

# Kyun-Seop Bae

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1148780/publications.pdf>

Version: 2024-02-01

115  
papers

1,482  
citations

393982

19  
h-index

377514

34  
g-index

119  
all docs

119  
docs citations

119  
times ranked

2560  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by <i>Plasmodium vivax</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1468-1475.	1.4	154
2	Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 266-273.	2.3	76
3	Pharmacokinetics and Pharmacodynamics of Propofol Microemulsion and Lipid Emulsion after an Intravenous Bolus and Variable Rate Infusion. <i>Anesthesiology</i> , 2007, 106, 924-934.	1.3	66
4	Pharmacokinetic and Pharmacodynamic Evaluation of a Novel Proton Pump Inhibitor, YH1885, in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 73-82.	1.0	63
5	The Thickness and Texture of Temporal Bone in Brain CT Predict Acoustic Window Failure of Transcranial Doppler. <i>Journal of Neuroimaging</i> , 2006, 16, 347-352.	1.0	63
6	Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1095-1105.	2.0	62
7	Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. <i>Clinical Therapeutics</i> , 2010, 32, 1178-1187.	1.1	62
8	Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1222-1230.	2.0	55
9	Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 751-759.	1.9	51
10	Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 111-116.	0.8	37
11	Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1108-1116.	1.0	35
12	Relationship between nurse staffing level and adult nursing-sensitive outcomes in tertiary hospitals of Korea: Retrospective observational study. <i>International Journal of Nursing Studies</i> , 2018, 80, 155-164.	2.5	33
13	Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 228-236.	2.3	32
14	Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 595-608.	0.7	31
15	Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug-Drug Interaction Study in Healthy Male Korean Volunteers. <i>Clinical Therapeutics</i> , 2012, 34, 1182-1194.	1.1	30
16	A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1609-1617.	1.1	29
17	Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. <i>British Journal of Cancer</i> , 2011, 104, 605-612.	2.9	24
18	Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 473-480.	1.1	23

#	ARTICLE	IF	CITATIONS
19	Standard Error of Empirical Bayes Estimate in NONMEM <sup>®</sup> VI. Korean Journal of Physiology and Pharmacology, 2012, 16, 97.	0.6	22
20	A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel. Investigational New Drugs, 2013, 31, 616-622.	1.2	20
21	A Phase I Study of <i>UGT1A1</i> * <i>28</i> * <i>6</i> Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI. Oncology, 2015, 88, 164-172.	0.9	19
22	A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 6182-6186.	3.2	18
23	First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies. Investigational New Drugs, 2015, 33, 1048-1057.	1.2	18
24	A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer. Oncologist, 2017, 22, 129-e8.	1.9	18
25	Single nucleotide polymorphism of Wilms <sup>™</sup> tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. Annals of Hematology, 2012, 91, 671-677.	0.8	17
26	Pharmacokinetic Interaction of Telmisartan With S-Amlodipine: An Open-Label, Two-Period Crossover Study in Healthy Korean Male Volunteers. Clinical Therapeutics, 2012, 34, 1625-1635.	1.1	16
27	Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Male Korean Volunteers. Clinical Therapeutics, 2015, 37, 563-573.	1.1	16
28	Evaluation of Pharmacokinetic and Pharmacodynamic Profiles and Tolerability After Single (2.5, 5, or 10) mg of Telmisartan in Healthy Korean Volunteers. Clinical Therapeutics, 2013, 35, 819-835.	1.1	14
29	Population Pharmacokinetic Analysis of Simvastatin and its Active Metabolite with the Characterization of Atypical Complex Absorption Kinetics. Pharmaceutical Research, 2014, 31, 1801-1812.	1.7	13
30	Predicting the Efficacy of an Oral Paclitaxel Formulation (DHP107) Through Modeling and Simulation. Clinical Therapeutics, 2015, 37, 402-417.	1.1	13
31	Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2015, 75, 97-109.	1.1	13
32	Pharmacokinetics, Pharmacodynamics, and Tolerability of Single-Dose Oral LCB01-0371, a Novel Oxazolidinone with Broad-Spectrum Activity, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	13
33	Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II. European Journal of Clinical Pharmacology, 2006, 63, 17-26.	0.8	12
34	A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean Patients. Korean Journal of Physiology and Pharmacology, 2012, 16, 273.	0.6	12
35	Pharmacokinetic Interaction Between Pitavastatin and Valsartan: A Randomized, Open-Labelled Crossover Study in Healthy Male Korean Volunteers. Clinical Therapeutics, 2012, 34, 958-965.	1.1	12
36	Bioavailability and Tolerability of Combination Treatment With Revaprazan 200 mg + Itopride 150 mg: A Randomized Crossover Study in Healthy Male Korean Volunteers. Clinical Therapeutics, 2012, 34, 1999-2010.	1.1	11

#	ARTICLE	IF	CITATIONS
37	Development of R packages: <i>NonCompart</i> ™ and <i>ncar</i> ™ for noncompartmental analysis (NCA). <i>Translational and Clinical Pharmacology</i> , 2018, 26, 10.	0.3	11
38	Pharmacokinetic Interactions Between Eperisone Hydrochloride and Aceclofenac: A Randomized, Open-Label, Crossover Study of Healthy Korean Men. <i>Clinical Therapeutics</i> , 2013, 35, 1528-1535.	1.1	10
39	Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. <i>Current Medical Research and Opinion</i> , 2015, 31, 229-241.	0.9	10
40	Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 815-821.	2.0	10
41	Estimation of indocyanine green elimination rate constant $k$ and retention rate at 15 min using patient age, weight, bilirubin, and albumin. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2009, 16, 521-528.	2.0	9
42	Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1419.	2.0	9
43	R-based reproduction of the estimation process hidden behind NONMEM® Part 2: First-order conditional estimation. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 161.	0.3	9
44	Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral LCB01-0371 in Healthy Male Volunteers. <i>Clinical Therapeutics</i> , 2018, 40, 2050-2064.	1.1	9
45	Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. <i>Oncotarget</i> , 2017, 8, 41387-41400.	0.8	9
46	Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: An open-label, randomized-sequence, three-treatment, three-way crossover study. <i>Clinical Therapeutics</i> , 2009, 31, 1046-1053.	1.1	8
47	R-based reproduction of the estimation process hidden behind NONMEM® Part 1: first-order approximation method. <i>Translational and Clinical Pharmacology</i> , 2015, 23, 1.	0.3	8
48	Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371. <i>Clinical Therapeutics</i> , 2019, 41, 92-106.	1.1	8
49	Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of Tegoprazan. <i>Clinical Therapeutics</i> , 2021, 43, 1371-1380.	1.1	8
50	The pharmacokinetics of letrozole – its association with key body mass metrics. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 557-565.	0.3	8
51	Pharmacokinetic Comparison of 2 Formulations of Anastrozole (1 mg) in Healthy Korean Male Volunteers: A Randomized, Single-Dose, 2-Period, 2-Sequence, Crossover Study. <i>Clinical Therapeutics</i> , 2012, 34, 305-313.	1.1	7
52	Evaluation of Pharmacokinetic Drug Interactions Between Gemigliptin (Dipeptidylpeptidase-4 Inhibitor) and Glimepiride (Sulfonylurea) in Healthy Volunteers. <i>Drugs in R and D</i> , 2014, 14, 165-176.	1.1	7
53	Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3571.	2.0	7
54	Prediction of plasma caffeine concentrations in young adolescents following ingestion of caffeinated energy drinks: a Monte Carlo simulation. <i>European Journal of Pediatrics</i> , 2015, 174, 1671-1678.	1.3	7

#	ARTICLE	IF	CITATIONS
55	A phase I trial to determine the maximum tolerated dose and evaluate the safety and pharmacokinetics (PK) of docetaxel-PNP, polymeric nanoparticle formulation of docetaxel, in subjects with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13104-e13104.	0.8	7
56	&lt;p&gt;Pharmacokinetic Evaluation by Modeling and Simulation Analysis of a Donepezil Patch Formulation in Healthy Male Volunteers&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1729-1737.	2.0	7
57	Dose proportionality and pharmacokinetics of&nbsp;carvedilol sustained-release formulation: a&nbsp;single dose-ascending 10-sequence incomplete block study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2911.	2.0	6
58	Pharmacokinetic interaction between udenafil and&nbsp;dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1209.	2.0	6
59	Quantitative Modeling Analysis Demonstrates the Impact of <i>CYP2C19</i> and <i>CYP2D6</i> Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 532-540.	1.0	6
60	Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg &A— 2 tablets) fixeddose combination tablet in healthy male volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 381-391.	0.3	6
61	Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 784, 25-31.	1.2	5
62	Effects of Ketoconazole on the Pharmacokinetic Properties of CG100649, A Novel NSAID: A Randomized, Open-Label Crossover Study in Healthy Korean Male Volunteers. <i>Clinical Therapeutics</i> , 2014, 36, 115-125.	1.1	5
63	Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 967-977.	0.8	5
64	Population plasma and urine pharmacokinetics of ivabradine and its active metabolite S18982 in healthy Korean volunteers. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 439-449.	1.0	5
65	Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 905-912.	1.0	5
66	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. <i>Investigational New Drugs</i> , 2018, 36, 877-885.	1.2	5
67	Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Potassium Channel Opener, SKP-450, in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 752-761.	1.0	4
68	<p>First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP&Eribose) Polymerase&E1 Inhibitor, JPI-289, in Healthy Volunteers</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3189-3199.	2.0	4
69	A Simulation Study to Compare the Treatment Effect of Tamoxifen byCYP2D6Genotypes and Third-Generation Aromatase Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1088-1096.	1.0	3
70	Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin. <i>Pharmaceutical Research</i> , 2019, 36, 146.	1.7	3
71	Analytical solution of linear multi-compartment models with non-zero initial condition and its implementation with R. <i>Translational and Clinical Pharmacology</i> , 2019, 27, 43.	0.3	3
72	Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers. <i>Xenobiotica</i> , 2020, 50, 288-296.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis. <i>Clinical Therapeutics</i> , 2022, 44, 67-80.e1.	1.1	3
74	Pharmacokinetic Characteristics of Ibandronate and Tolerability of DP-R206 (150 mg) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td (Ibar Healthy Adults. <i>Translational and Clinical Pharmacology</i> , 2014, 22, 22.	0.3	2
75	Modeling and simulation analysis of the relationship between lesion recurrence on brain images and clinical recurrence in patients with ischemic stroke. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 458-466.	1.0	2
76	Pharmacokinetic, Pharmacodynamic, and Safety/Tolerability Profiles of CG100649, a Novel COX-2 Inhibitor: Results of a Phase I, Randomized, Multiple-dose Study in Healthy Korean Men and Women. <i>Clinical Therapeutics</i> , 2015, 37, 197-210.	1.1	2
77	Caffsim: simulation of plasma caffeine concentrations implemented as an R package and Web-applications. <i>Translational and Clinical Pharmacology</i> , 2017, 25, 141.	0.3	2
78	First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1111-e1120.	1.8	2
79	First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3107-3107.	0.8	2
80	A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 605-613.	0.3	2
81	Assessment of the influence of severe renal impairment on the pharmacokinetics of mirodenafil in Korean male volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 880-888.	0.3	2
82	Abstract LB-359: Extended accumulation of acetylated histone in tumor tissues obtained from the phase I study of CG200745. <i>Cancer Research</i> , 2012, 72, LB-359-LB-359.	0.4	2
83	Validation of â€œsasLM,â€œan R package for linear models with type III sum of squares. <i>Translational and Clinical Pharmacology</i> , 2020, 28, 83.	0.3	2
84	Comparison of Pharmacokinetic Characteristics and Safety Between JW AmlodipineÂ® Tablet 5 mg and NovarscÂ® Tablet 5 mg in Healthy Male Volunteers. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2013, 21, 95.	0.1	1
85	Comparative Pharmacokinetics and Bioavailability of Gemifloxacin Administered as an Intravenous 200Âmg Formulation or an Oral 320Âmg Tablet. <i>Clinical Drug Investigation</i> , 2014, 34, 195-201.	1.1	1
86	Single and multiple dose pharmacokinetics and&nbsp;tolerability of HX-1171, a novel antioxidant, in healthy volunteers. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1735.	2.0	1
87	Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation. <i>Korean Journal of Physiology and Pharmacology</i> , 2016, 20, 245.	0.6	1
88	Forensic science meets clinical pharmacology: pharmacokinetic model based estimation of alcohol concentration of a defendant as requested by a local prosecutor's office. <i>Translational and Clinical Pharmacology</i> , 2017, 25, 5.	0.3	1
89	Bioequivalence data analysis for the case of separate hospitalization. <i>Translational and Clinical Pharmacology</i> , 2017, 25, 93.	0.3	1
90	Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1543-1550.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2565-2565.	0.8	1
92	A phase I/II study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors (phase I) and gastric cancer (phase II).. Journal of Clinical Oncology, 2014, 32, 101-101.	0.8	1
93	Pharmacokinetic Comparison of Controlled- and Immediate-Release Formulations of Dexibuprofen after Single and Multiple Oral Doses in Fasting Healthy Male Korean Volunteers. Clinical Therapeutics, 2011, 33, 1132-1141.	1.1	0
94	Comparison of Pharmacokinetics and Safety of Two Formulations of Letrozole (2.5 mg) in Healthy Male Volunteers. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2012, 20, 135.	0.1	0
95	Targeted Plasma Metabolite Profiling of Metformin in Healthy Korean Volunteers. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2012, 20, 175.	0.1	0
96	Comparison of Pharmacokinetic Characteristics and the Safety between Amlodipine Maleate Tablet 5 mg and Amlodipine Besylate Tablet 5 mg. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2012, 20, 42.	0.1	0
97	Bioequivalence of HCP1104, a New Fixed Dose Combination Drug and Co-administration of Eperisone 50 mg and Aceclofenac 100 mg: A Partial Replicated Crossover Study Design to Estimate the Pharmacokinetics of Highly Variable Drugs. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2013, 21, 120.	0.1	0
98	Pharmacodynamic Comparison of Two Formulations of Voglibose 0.3-mg Tablet. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2013, 21, 34.	0.1	0
99	Pharmacokinetics, Tolerability, and Safety of the Single Oral Administration of AGSAV301 vs Exforge: A Randomized Crossover Study of Healthy Male Volunteers. American Journal of Cardiovascular Drugs, 2014, 14, 63-72.	1.0	0
100	Corrigendum to "Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Korean Male Volunteers"™. Clinical Therapeutics, 2015, 37, 2149.	1.1	0
101	Tolerability and Pharmacokinetics of Two Formulations of Megestrol Acetate under Fed Conditions in Healthy Volunteers. Clinical Therapeutics, 2015, 37, 439-447.	1.1	0
102	Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine. Translational and Clinical Pharmacology, 2016, 24, 90.	0.3	0
103	Process Innovation Improves Trial Operation Efficiency. Therapeutic Innovation and Regulatory Science, 2016, 50, 510-514.	0.8	0
104	Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects. Journal of Korean Medical Science, 2018, 33, e258.	1.1	0
105	Acetaminophen-induced anaphylaxis: a case report. Translational and Clinical Pharmacology, 2021, 29, 88.	0.3	0
106	Study Design and Analysis for Creating Bridging Data. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2002, 10, 204.	0.1	0
107	Validation of the Assay for the Glucose of Human Venous Blood Using a Handy Blood Sugar Measuring Instrument. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2002, 10, 34.	0.1	0
108	Population Pharmacokinetics of Cefepime in Febrile Neutropenic Patients. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2003, 11, 23.	0.1	0

#	ARTICLE	IF	CITATIONS
109	Population Pharmacokinetic Analysis of Anastrozole in Healthy Korean male Volunteers. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2010, 18, 23.	0.1	0
110	Phase I clinical, pharmacokinetic, and pharmacodynamic study of CG200745, a histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, e13560-e13560.	0.8	0
111	Validation of LC-MS/MS Method for Determination of Bivalirudin in Human Plasma: Application to a Pharmacokinetic Study. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2013, 21, 166.	0.1	0
112	Population Pharmacokinetics of Vancomycin in Korean Patients. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 1998, 6, 142.	0.1	0
113	Development of a validated liquid chromatography-tandem mass spectrometry assay for the quantification of simvastatin acid, the active metabolite of simvastatin, in human plasma. Translational and Clinical Pharmacology, 2016, 24, 22.	0.3	0
114	Bioequivalence data analysis. Translational and Clinical Pharmacology, 2020, 28, 175.	0.3	0
115	A simple time-to-event model with NONMEM featuring right-censoring. Translational and Clinical Pharmacology, 2022, 30, 75.	0.3	0